Mesothelioma in situ of the peritoneum: report of three cases and review of the literature

Histopathology. 2024 Feb;84(3):492-506. doi: 10.1111/his.15092. Epub 2023 Dec 12.

Abstract

Aim: Diagnosis of mesothelioma in situ (MIS) is historically controversial and, until recently, specific features defining the entity have not been well characterized. Most reported cases of MIS occurred in the pleura; peritoneal MIS is very rare. This study investigates the morphologic features and results of ancillary testing in peritoneal MIS.

Methods: We present three patients with peritoneal MIS, as defined by a single layer of mesothelial cells with loss of nuclear BRCA-1-associated protein-1 (BAP1) immunostaining and without evidence of invasive tumour by microscopic evaluation, imaging, or direct examination of the peritoneum. Histology and immunostains were reviewed by three expert thoracic pathologists with multidisciplinary input. Next-generation sequencing (NGS) was performed in all three cases. A literature review was conducted to characterize this rare precursor lesion.

Results: BAP1 was lost in all three lesions, while methylthioadenosine phosphorylase (MTAP) was retained in two (not performed in the third). NGS revealed BAP1 pathogenic alterations in all three cases as well as mutations of SMO, ERCC3, TET2, and U2AF1. Progression to invasive mesothelioma occurred in one patient at 13 months postdiagnosis (case 1). One patient was diagnosed at age 24 and was later found to harbour a BAP1 germline mutation (case 3).

Conclusion: This work describes the histologic features and clinicopathologic characteristics of peritoneal MIS in three cases, highlights BAP1 somatic and germline mutations in peritoneal MIS, and strengthens the importance of ancillary studies (including immunohistochemical and molecular studies) in the diagnosis of MIS.

Keywords: BAP1; mesothelioma in situ; molecular study; peritoneum.

Publication types

  • Review
  • Case Reports

MeSH terms

  • Biomarkers, Tumor / genetics
  • Humans
  • Lung Neoplasms* / pathology
  • Mesothelioma* / diagnosis
  • Mesothelioma* / genetics
  • Mesothelioma* / pathology
  • Mesothelioma, Malignant*
  • Peritoneal Neoplasms* / diagnosis
  • Peritoneal Neoplasms* / genetics
  • Peritoneal Neoplasms* / pathology
  • Peritoneum / pathology
  • Ubiquitin Thiolesterase / genetics
  • Young Adult

Substances

  • Biomarkers, Tumor
  • Ubiquitin Thiolesterase